Rituximab Improves Burkitt Lymphoma Survival at a High Price

Burkitt lymphoma hits many children in Tanzania hard. Only about half survive two years with standard chemo. A recent study in Tanzania and Uganda added a drug called rituximab to the usual treatment. Kids who got the combo lived longer after one year. No extra bad side effects showed up.

Researchers then did a cost check. They built a math model to see if the extra drug is worth the money. They measured health gains in something called DALYs. They compared the cost per DALY saved to three price tags. The result came in at $483 per DALY. That is just above the strictest cutoff of $411. But it passes the higher cutoffs easily.

The drug works best for kids with advanced disease. For them the cost per DALY drops to $395. The numbers change a lot if the drug price shifts or if you change how you count future benefits. The model also says the country would need about $160 million each year five years from now to pay for this.

That is a huge bill for a low income health system. It raises tough questions. Can the government afford it? Will donors step in? Could the drug maker lower the price? Saving young lives matters but so does keeping the whole health system running.

Decision makers have to balance hope and reality. Every child saved is a win. Yet the money must come from somewhere. This analysis gives them a clear picture to start that conversation.